Two Sigma Investments LP Purchases 103,574 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Two Sigma Investments LP raised its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 13.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 846,766 shares of the biopharmaceutical company's stock after purchasing an additional 103,574 shares during the quarter. Two Sigma Investments LP owned about 1.56% of Emergent BioSolutions worth $8,095,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of EBS. American Century Companies Inc. lifted its position in shares of Emergent BioSolutions by 23.4% in the fourth quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company's stock worth $20,437,000 after purchasing an additional 404,667 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Emergent BioSolutions by 70.9% during the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock worth $14,722,000 after purchasing an additional 638,995 shares during the period. Millennium Management LLC lifted its position in shares of Emergent BioSolutions by 83.0% in the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company's stock worth $14,167,000 after acquiring an additional 671,947 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company's stock valued at $10,554,000 after acquiring an additional 444,790 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Emergent BioSolutions by 8.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company's stock valued at $8,626,000 after purchasing an additional 69,157 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on EBS shares. Wall Street Zen lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, April 1st.

Emergent BioSolutions Stock Performance

Shares of EBS traded down $0.08 during trading hours on Friday, hitting $6.39. The company had a trading volume of 170,210 shares, compared to its average volume of 1,843,194. The business has a fifty day moving average of $5.29 and a 200-day moving average of $7.59. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a market cap of $346.57 million, a price-to-earnings ratio of -1.56 and a beta of 2.09. Emergent BioSolutions Inc. has a 12 month low of $4.02 and a 12 month high of $15.10.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping analysts' consensus estimates of $0.49 by $0.22. The business had revenue of $222.20 million for the quarter, compared to analyst estimates of $218.50 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. Equities analysts anticipate that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions announced that its Board of Directors has approved a stock buyback plan on Monday, March 31st that authorizes the company to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Keith Katkin sold 7,844 shares of Emergent BioSolutions stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total transaction of $49,417.20. Following the transaction, the director now owns 86,431 shares in the company, valued at approximately $544,515.30. This trade represents a 8.32% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.